 | • レポートコード：MRC2-11QY12162 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は肝性脳症（HE）治療薬のグローバル市場について調査・分析したレポートです。種類別（ラクツロース、リファキシミン、ネオマイシン、プロバイオティクス、チアミン）市場規模、用途別（急性肝不全、肝硬変）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別肝性脳症（HE）治療薬の競争状況、市場シェア ・世界の肝性脳症（HE）治療薬市場：種類別市場規模 2015年-2020年（ラクツロース、リファキシミン、ネオマイシン、プロバイオティクス、チアミン） ・世界の肝性脳症（HE）治療薬市場：種類別市場規模予測 2021年-2026年（ラクツロース、リファキシミン、ネオマイシン、プロバイオティクス、チアミン） ・世界の肝性脳症（HE）治療薬市場：用途別市場規模 2015年-2020年（急性肝不全、肝硬変） ・世界の肝性脳症（HE）治療薬市場：用途別市場規模予測 2021年-2026年（急性肝不全、肝硬変） ・北米の肝性脳症（HE）治療薬市場分析：米国、カナダ ・ヨーロッパの肝性脳症（HE）治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの肝性脳症（HE）治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の肝性脳症（HE）治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの肝性脳症（HE）治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：ASKA Pharmaceutical、COSMO PHARMACEUTICALS、Mallinckrodt、Valeant ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
HE is a potentially fatal brain disorder that is caused by liver damage, which results in the failure to remove toxins from the blood.
The availability of patient-focused programs to assist disease management is one of the primary growth drivers for the global hepatic encephalopathy (HE) therapeutics market till 2023. Such programs increase the adherence to therapeutics by improving convenience for patients. Norgine collaborated with the European liver patients association (ELPA) to launch Time to DeLiver program, which is focused on changing the perception about HE among all stakeholders, healthcare professionals, and policymakers. This in turn, drives the demand for diagnosis and management of HE.
Market Analysis and Insights: Global Hepatic Encephalopathy (HE) Therapeutics Market
The global Hepatic Encephalopathy (HE) Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Hepatic Encephalopathy (HE) Therapeutics Scope and Market Size
Hepatic Encephalopathy (HE) Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Hepatic Encephalopathy (HE) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
ASKA Pharmaceutical
COSMO PHARMACEUTICALS
Mallinckrodt
Valeant
…
Market segment by Type, the product can be split into
Lactulose
Rifaximin
Neomycin
Probiotics
Thiamine
Market segment by Application, split into
Acute Liver Failure
Liver Cirrhosis
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Hepatic Encephalopathy (HE) Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Lactulose
1.4.3 Rifaximin
1.4.4 Neomycin
1.4.5 Probiotics
1.4.6 Thiamine
1.5 Market by Application
1.5.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Acute Liver Failure
1.5.3 Liver Cirrhosis
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Perspective (2015-2026)
2.2 Global Hepatic Encephalopathy (HE) Therapeutics Growth Trends by Regions
2.2.1 Hepatic Encephalopathy (HE) Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Hepatic Encephalopathy (HE) Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Hepatic Encephalopathy (HE) Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Hepatic Encephalopathy (HE) Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Hepatic Encephalopathy (HE) Therapeutics Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Hepatic Encephalopathy (HE) Therapeutics Players by Market Size
3.1.1 Global Top Hepatic Encephalopathy (HE) Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Hepatic Encephalopathy (HE) Therapeutics Market Concentration Ratio
3.2.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Hepatic Encephalopathy (HE) Therapeutics Revenue in 2019
3.3 Hepatic Encephalopathy (HE) Therapeutics Key Players Head office and Area Served
3.4 Key Players Hepatic Encephalopathy (HE) Therapeutics Product Solution and Service
3.5 Date of Enter into Hepatic Encephalopathy (HE) Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Hepatic Encephalopathy (HE) Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Hepatic Encephalopathy (HE) Therapeutics Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2015-2020)
5.2 Global Hepatic Encephalopathy (HE) Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Hepatic Encephalopathy (HE) Therapeutics Market Size (2015-2020)
6.2 Hepatic Encephalopathy (HE) Therapeutics Key Players in North America (2019-2020)
6.3 North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2015-2020)
6.4 North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2015-2020)
7 Europe
7.1 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size (2015-2020)
7.2 Hepatic Encephalopathy (HE) Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2015-2020)
7.4 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2015-2020)
8 China
8.1 China Hepatic Encephalopathy (HE) Therapeutics Market Size (2015-2020)
8.2 Hepatic Encephalopathy (HE) Therapeutics Key Players in China (2019-2020)
8.3 China Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2015-2020)
8.4 China Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2015-2020)
9 Japan
9.1 Japan Hepatic Encephalopathy (HE) Therapeutics Market Size (2015-2020)
9.2 Hepatic Encephalopathy (HE) Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2015-2020)
9.4 Japan Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Hepatic Encephalopathy (HE) Therapeutics Market Size (2015-2020)
10.2 Hepatic Encephalopathy (HE) Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2015-2020)
11 India
11.1 India Hepatic Encephalopathy (HE) Therapeutics Market Size (2015-2020)
11.2 Hepatic Encephalopathy (HE) Therapeutics Key Players in India (2019-2020)
11.3 India Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2015-2020)
11.4 India Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Hepatic Encephalopathy (HE) Therapeutics Market Size (2015-2020)
12.2 Hepatic Encephalopathy (HE) Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 ASKA Pharmaceutical
13.1.1 ASKA Pharmaceutical Company Details
13.1.2 ASKA Pharmaceutical Business Overview
13.1.3 ASKA Pharmaceutical Hepatic Encephalopathy (HE) Therapeutics Introduction
13.1.4 ASKA Pharmaceutical Revenue in Hepatic Encephalopathy (HE) Therapeutics Business (2015-2020))
13.1.5 ASKA Pharmaceutical Recent Development
13.2 COSMO PHARMACEUTICALS
13.2.1 COSMO PHARMACEUTICALS Company Details
13.2.2 COSMO PHARMACEUTICALS Business Overview
13.2.3 COSMO PHARMACEUTICALS Hepatic Encephalopathy (HE) Therapeutics Introduction
13.2.4 COSMO PHARMACEUTICALS Revenue in Hepatic Encephalopathy (HE) Therapeutics Business (2015-2020)
13.2.5 COSMO PHARMACEUTICALS Recent Development
13.3 Mallinckrodt
13.3.1 Mallinckrodt Company Details
13.3.2 Mallinckrodt Business Overview
13.3.3 Mallinckrodt Hepatic Encephalopathy (HE) Therapeutics Introduction
13.3.4 Mallinckrodt Revenue in Hepatic Encephalopathy (HE) Therapeutics Business (2015-2020)
13.3.5 Mallinckrodt Recent Development
13.4 Valeant
13.4.1 Valeant Company Details
13.4.2 Valeant Business Overview
13.4.3 Valeant Hepatic Encephalopathy (HE) Therapeutics Introduction
13.4.4 Valeant Revenue in Hepatic Encephalopathy (HE) Therapeutics Business (2015-2020)
13.4.5 Valeant Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Hepatic Encephalopathy (HE) Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Hepatic Encephalopathy (HE) Therapeutics Revenue
Table 3. Ranking of Global Top Hepatic Encephalopathy (HE) Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Lactulose
Table 6. Key Players of Rifaximin
Table 7. Key Players of Neomycin
Table 8. Key Players of Probiotics
Table 9. Key Players of Thiamine
Table 10. Global Hepatic Encephalopathy (HE) Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Regions (2015-2020)
Table 14. Global Hepatic Encephalopathy (HE) Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Regions (2021-2026)
Table 16. Market Top Trends
Table 17. Key Drivers: Impact Analysis
Table 18. Key Challenges
Table 19. Hepatic Encephalopathy (HE) Therapeutics Market Growth Strategy
Table 20. Main Points Interviewed from Key Hepatic Encephalopathy (HE) Therapeutics Players
Table 21. Global Hepatic Encephalopathy (HE) Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 22. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Players (2015-2020)
Table 23. Global Top Hepatic Encephalopathy (HE) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hepatic Encephalopathy (HE) Therapeutics as of 2019)
Table 24. Global Hepatic Encephalopathy (HE) Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Hepatic Encephalopathy (HE) Therapeutics Product Solution and Service
Table 27. Date of Enter into Hepatic Encephalopathy (HE) Therapeutics Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 30. Global Hepatic Encephalopathy (HE) Therapeutics Market Size Share by Type (2015-2020)
Table 31. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Type (2021-2026)
Table 32. Global Hepatic Encephalopathy (HE) Therapeutics Market Size Share by Application (2015-2020)
Table 33. Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 34. Global Hepatic Encephalopathy (HE) Therapeutics Market Size Share by Application (2021-2026)
Table 35. North America Key Players Hepatic Encephalopathy (HE) Therapeutics Revenue (2019-2020) (Million US$)
Table 36. North America Key Players Hepatic Encephalopathy (HE) Therapeutics Market Share (2019-2020)
Table 37. North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 38. North America Hepatic Encephalopathy (HE) Therapeutics Market Share by Type (2015-2020)
Table 39. North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 40. North America Hepatic Encephalopathy (HE) Therapeutics Market Share by Application (2015-2020)
Table 41. Europe Key Players Hepatic Encephalopathy (HE) Therapeutics Revenue (2019-2020) (Million US$)
Table 42. Europe Key Players Hepatic Encephalopathy (HE) Therapeutics Market Share (2019-2020)
Table 43. Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 44. Europe Hepatic Encephalopathy (HE) Therapeutics Market Share by Type (2015-2020)
Table 45. Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 46. Europe Hepatic Encephalopathy (HE) Therapeutics Market Share by Application (2015-2020)
Table 47. China Key Players Hepatic Encephalopathy (HE) Therapeutics Revenue (2019-2020) (Million US$)
Table 48. China Key Players Hepatic Encephalopathy (HE) Therapeutics Market Share (2019-2020)
Table 49. China Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 50. China Hepatic Encephalopathy (HE) Therapeutics Market Share by Type (2015-2020)
Table 51. China Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 52. China Hepatic Encephalopathy (HE) Therapeutics Market Share by Application (2015-2020)
Table 53. Japan Key Players Hepatic Encephalopathy (HE) Therapeutics Revenue (2019-2020) (Million US$)
Table 54. Japan Key Players Hepatic Encephalopathy (HE) Therapeutics Market Share (2019-2020)
Table 55. Japan Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 56. Japan Hepatic Encephalopathy (HE) Therapeutics Market Share by Type (2015-2020)
Table 57. Japan Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 58. Japan Hepatic Encephalopathy (HE) Therapeutics Market Share by Application (2015-2020)
Table 59. Southeast Asia Key Players Hepatic Encephalopathy (HE) Therapeutics Revenue (2019-2020) (Million US$)
Table 60. Southeast Asia Key Players Hepatic Encephalopathy (HE) Therapeutics Market Share (2019-2020)
Table 61. Southeast Asia Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 62. Southeast Asia Hepatic Encephalopathy (HE) Therapeutics Market Share by Type (2015-2020)
Table 63. Southeast Asia Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 64. Southeast Asia Hepatic Encephalopathy (HE) Therapeutics Market Share by Application (2015-2020)
Table 65. India Key Players Hepatic Encephalopathy (HE) Therapeutics Revenue (2019-2020) (Million US$)
Table 66. India Key Players Hepatic Encephalopathy (HE) Therapeutics Market Share (2019-2020)
Table 67. India Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 68. India Hepatic Encephalopathy (HE) Therapeutics Market Share by Type (2015-2020)
Table 69. India Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 70. India Hepatic Encephalopathy (HE) Therapeutics Market Share by Application (2015-2020)
Table 71. Central & South America Key Players Hepatic Encephalopathy (HE) Therapeutics Revenue (2019-2020) (Million US$)
Table 72. Central & South America Key Players Hepatic Encephalopathy (HE) Therapeutics Market Share (2019-2020)
Table 73. Central & South America Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 74. Central & South America Hepatic Encephalopathy (HE) Therapeutics Market Share by Type (2015-2020)
Table 75. Central & South America Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 76. Central & South America Hepatic Encephalopathy (HE) Therapeutics Market Share by Application (2015-2020)
Table 77. ASKA Pharmaceutical Company Details
Table 78. ASKA Pharmaceutical Business Overview
Table 79. ASKA Pharmaceutical Product
Table 80. ASKA Pharmaceutical Revenue in Hepatic Encephalopathy (HE) Therapeutics Business (2015-2020) (Million US$)
Table 81. ASKA Pharmaceutical Recent Development
Table 82. COSMO PHARMACEUTICALS Company Details
Table 83. COSMO PHARMACEUTICALS Business Overview
Table 84. COSMO PHARMACEUTICALS Product
Table 85. COSMO PHARMACEUTICALS Revenue in Hepatic Encephalopathy (HE) Therapeutics Business (2015-2020) (Million US$)
Table 86. COSMO PHARMACEUTICALS Recent Development
Table 87. Mallinckrodt Company Details
Table 88. Mallinckrodt Business Overview
Table 89. Mallinckrodt Product
Table 90. Mallinckrodt Revenue in Hepatic Encephalopathy (HE) Therapeutics Business (2015-2020) (Million US$)
Table 91. Mallinckrodt Recent Development
Table 92. Valeant Company Details
Table 93. Valeant Business Overview
Table 94. Valeant Product
Table 95. Valeant Revenue in Hepatic Encephalopathy (HE) Therapeutics Business (2015-2020) (Million US$)
Table 96. Valeant Recent Development
Table 97. Research Programs/Design for This Report
Table 98. Key Data Information from Secondary Sources
Table 99. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Lactulose Features
Figure 3. Rifaximin Features
Figure 4. Neomycin Features
Figure 5. Probiotics Features
Figure 6. Thiamine Features
Figure 7. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Application: 2020 VS 2026
Figure 8. Acute Liver Failure Case Studies
Figure 9. Liver Cirrhosis Case Studies
Figure 10. Hepatic Encephalopathy (HE) Therapeutics Report Years Considered
Figure 11. Global Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Regions: 2020 VS 2026
Figure 13. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Players in 2019
Figure 16. Global Top Hepatic Encephalopathy (HE) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hepatic Encephalopathy (HE) Therapeutics as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Hepatic Encephalopathy (HE) Therapeutics Revenue in 2019
Figure 18. North America Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Hepatic Encephalopathy (HE) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Bottom-up and Top-down Approaches for This Report
Figure 26. Data Triangulation
Figure 27. Key Executives Interviewed
顕性肝性脳症（OHE）の世界市場（～2026年） Hepatic encephalopathy (HE) is an altered level of consciousness as a result of liver failure. Onset may be gradual or sudden. Other symptoms may include movement problems, changes in mood, or changes in personality. In the advanced stages it can result in a coma. Overt hepatic encephalopathy develo…- 肝性脳症治療薬の世界市場（～2026年） Market Analysis and Insights: Global Hepatic Encephalopathy Drug Market The global Hepatic Encephalopathy Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Hepatic Encephalopathy Drug Scope and Market Size Hepatic E…
- 慢性外傷性脳症（CTE）の世界市場（～2026年） Chronic traumatic encephalopathy (CTE) is a kind of degenerative brain disease that is found in athletes, military veterans, and others with a history of repetitive brain trauma. Market Analysis and Insights: Global Chronic Traumatic Encephalopathy (CTE) Market The global Chronic Traumatic Encephalo…
- 急性腎不全治療薬の世界市場（～2026年） Acute renal failure is a sudden loss of kidney’s ability to eliminate excess fluids, salts and metabolic waste from the body. It leads to accumulation of metabolic waste and electrolytes in the body which can be life-threatening. Kidney eliminates creatinine (Metabolic waste) from the body. Acute re…
- 急性心不全（AHF）治療薬の世界市場（～2026年） Market Analysis and Insights: Global Acute Heart Failure (AHF) Therapeutics Market The global Acute Heart Failure (AHF) Therapeutics market size is projected to reach US$ 336 million by 2026, from US$ 262.2 million in 2020, at a CAGR of 26.8%% during 2021-2026. Global Acute Heart Failure (AHF) Thera…